A Phase 1b, Open-label, Single-arm, Dose-escalation Study of PN20 in Patients with Primary Immune Thrombocytopenia (ITP)
Latest Information Update: 24 Mar 2025
At a glance
- Drugs PN 20 (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Adverse reactions
- Sponsors Chongqing Peg-Bio Biopharm
- 24 Mar 2025 New trial record